Max Putman | Research Associate, Genmab
As a Research Associate in the Translational Research department at Genmab, I bridge in vitro and in vivo experimentation to help translate foundational scientific insights into clinically relevant applications. My work centers on the design, execution, and interpretation of diverse immunological and cellular assays—including binding assays, CDC assays, internalization assays, cytotoxicity assays, and complex DC/tumor co-cultures. I’m currently expanding my focus toward triple cultures involving dendritic cells, T-cells, and tumor cells to better mimic tumor immunology in vitro.
Genmab is my first role since graduating with a degree in Biomedical Laboratory Research, and it’s been a great place for me to grow both technically and scientifically so far. I take a hands-on and proactive approach in the lab, often working independently to set up, optimize, and troubleshoot experiments. I frequently work with platforms like the Incucyte for live-cell imaging and flow cytometry to capture detailed insights into cell behavior and immune responses. Beyond running assays, I also analyze and interpret the resulting data and use it to present findings and help steer project decisions within the team.
Furthermore, I'm part of a small AI working group within our team, helping colleagues explore how tools like ChatGPT can make our daily work more efficient and insightful.
My interest in research has always come from wanting to understand complex biological systems and turn that knowledge into something meaningful—something that can ultimately help patients. That’s also what I value most about working at Genmab: the focus on science with real impact.
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. To help develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | |
|
© Copyright 2020 by Hyphen Projects